Intranasal delivery of SARS-CoV-2 spike protein is sufficient to cause olfactory damage, inflammation and olfactory dysfunction in zebrafish
Brain, Behavior, and Immunity, ISSN: 0889-1591, Vol: 102, Page: 341-359
2022
- 37Citations
- 42Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations37
- Citation Indexes36
- CrossRef36
- 28
- Patent Family Citations1
- Patent Families1
- Captures42
- Readers42
- 42
- Mentions1
- News Mentions1
- News1
Most Recent News
Studies from University of New Mexico Add New Findings in the Area of COVID-19 (Intranasal Delivery of Sars-cov-2 Spike Protein Is Sufficient To Cause Olfactory Damage, Inflammation and Olfactory Dysfunction In Zebrafish)
2022 NOV 03 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx COVID-19 Daily -- Investigators publish new report on Coronavirus - COVID-19. According
Article Description
Anosmia, loss of smell, is a prevalent symptom of SARS-CoV-2 infection. Anosmia may be explained by several mechanisms driven by infection of non-neuronal cells and damage in the nasal epithelium rather than direct infection of olfactory sensory neurons (OSNs). Previously, we showed that viral proteins are sufficient to cause neuroimmune responses in the teleost olfactory organ (OO). We hypothesize that SARS-CoV-2 spike (S) protein is sufficient to cause olfactory damage and olfactory dysfunction. Using an adult zebrafish model, we report that intranasally delivered SARS-CoV-2 S RBD mostly binds to the non-sensory epithelium of the olfactory organ and causes severe olfactory histopathology characterized by loss of cilia, hemorrhages and edema. Electrophysiological recordings reveal impaired olfactory function to both food and bile odorants in animals treated intranasally with SARS-CoV-2 S RBD. However, no loss of behavioral preference for food was detected in SARS-CoV-2 S RBD treated fish. Single cell RNA-Seq of the adult zebrafish olfactory organ indicated widespread loss of olfactory receptor expression and inflammatory responses in sustentacular, endothelial, and myeloid cell clusters along with reduced numbers of T regs. Combined, our results demonstrate that intranasal SARS-CoV-2 S RBD is sufficient to cause structural and functional damage to the zebrafish olfactory system. These findings may have implications for intranasally delivered vaccines against SARS-CoV-2.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0889159122000745; http://dx.doi.org/10.1016/j.bbi.2022.03.006; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85126707320&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/35307504; https://linkinghub.elsevier.com/retrieve/pii/S0889159122000745; https://dx.doi.org/10.1016/j.bbi.2022.03.006
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know